CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cerulean Pharma Inc. (Nasdaq: CERU), a leader in Dynamic Tumor Targeting™, today provided an update on corporate activities during the quarter ended December 31, 2014, and reported progress with its clinical development programs.
“Today, Cerulean made the important announcement that the Phase 1b/2 trial of CRLX101 in combination with Avastin® in relapsed renal cell carcinoma, or RCC, that completed enrollment in the fourth quarter met its primary endpoint,” said Paul Friedman, M.D., Executive Chairman of Cerulean.
Help employers find you! Check out all the jobs and post your resume.
